

113. (New) The antibody or antigen-binding fragment of Claim 24 wherein said antibody or antigen-binding fragment inhibits transient increase in the concentration of cytosolic free calcium ( $[Ca^{2+}]_i$ ) induced upon binding of ligand to said Bonzo.
114. (New) The antibody or antigen-binding fragment of Claim 35 wherein said antibody or antigen-binding fragment inhibits transient increase in the concentration of cytosolic free calcium ( $[Ca^{2+}]_i$ ) induced upon binding of ligand to said Bonzo.
115. (New) A method of inhibiting a Bonzo function comprising contacting a cell that expresses Bonzo with an antibody or antigen-binding fragment thereof which binds mammalian Bonzo and inhibits the binding of ligand thereto, thereby inhibiting the function of said Bonzo.

#### REMARKS

Claims 51, 58, 67, 69, 77, 80 and 89-94 have been cancelled without prejudice. Claims 16, 24-26, 35-37, 47, 53 and 60 have been amended, and new Claims 113-115 have been added. Claims 16, 21-47, 53, 60, 84, 88 and 97-115 are pending.

Claims 16, 47, 53 and 60 have been amended to recite "an antibody or antigen-binding fragment thereof which binds mammalian Bonzo and inhibits the binding of ligand thereto."

Claim 16 has been further amended to delete "wherein said Bonzo binding agent is not platelet factor-4."

Claims 24-26, 35-37 have been amended and new Claims 113 and 114 have been added to more particularly point out the claimed subject matter.

Support for the amendments is found throughout the application, for example, at page 3, lines 17-26; page 36, lines 2 through 8; page 47, line 1 *et seq.*; and page 52, line 19 *et seq.*

The amended claims and new claims are supported by the application as filed. Therefore, this amendment adds no new matter.

Restriction Requirement

Responsive to the Restriction Requirement dated May 12, 2003, the claims of Group III (Claims 21-46, 84, 88, 97-112 and new Claims 113 and 114) drawn to an antibody or antigen-binding fragment thereof that binds Bonzo and inhibits the binding of a ligand thereto, a kit comprising such an antibody or antigen-binding fragment, and a cell that produces such an antibody or antigen-binding fragment, are elected for prosecution. Applicants reserve the right to file a continuing application or take such other appropriate action as deemed necessary to protect the non-elected inventions. Applicants do not hereby abandon or waive any rights in the non-elected inventions.

Anticipated Rejoinder of Claims Pursuant to M.P.E.P. § 821.04

Non-elected Claims 16, 47, 53 and 60 have been amended to recite, and new Claim 115 recites, "an antibody or antigen-binding fragment thereof which binds mammalian Bonzo and inhibits the binding of ligand thereto." These claims are drawn to processes of using the antibody or antigen-binding fragment product of the Group III invention. Therefore, if product Claim 21 is found to be allowable, then method Claims 16, 47, 53, 60 and 115 should also be allowable. Applicants request, pursuant to U.S. Patent Office practice (M.P.E.P. § 821.04), that Claims 16, 47, 53, 60 and 115 be rejoined if Claim 21 is found to be allowable.

Information Disclosure Statement


An Information Disclosure Statement (IDS) was filed on August 27, 2001. Acknowledgment of consideration of the information provided therein is requested in the next Office Communication.

CONCLUSION

In view of the above amendments and remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned at (978) 341-0036.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 

Robert H. Underwood

Registration No. 45,170

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: June 10, 2003



MARKED UP VERSION OF AMENDMENTS

Claim Amendments Under 37 C.F.R. § 1.121(c)(1)(ii)

Claims 51, 58, 67, 69, 77, 80 and 89-94 have been cancelled.

16. (Amended) A method of detecting a mammalian Bonzo or portion thereof in a biological sample, comprising:
  - a) contacting a biological sample with [~~a Bonzo-binding agent~~] an antibody or antigen-binding fragment thereof which binds mammalian Bonzo and inhibits the binding of ligand thereto, under conditions appropriate for binding of said [~~agent~~] antibody or antigen-binding fragment to mammalian Bonzo or a portion thereof; and
  - b) detecting binding of said [~~agent thereto~~] antibody or antigen-binding fragment to said Bonzo or portion thereof;

wherein the binding of said [~~agent~~] antibody or antigen-binding fragment to said Bonzo or portion thereof indicates the presence of said Bonzo or portion thereof [~~and wherein said Bonzo-binding agent is not platelet factor-4~~].
  
24. (Twice Amended) The antibody or antigen-binding fragment of Claim 21 wherein said antibody or antigen-binding fragment inhibits signal transduction and/or a cellular response [~~to~~] induced upon binding of ligand to said Bonzo in an *in vitro* assay with an IC<sub>50</sub> of less than about 7 µg/mL.
  
25. (Amended) The antibody or antigen-binding fragment of Claim 24 wherein said antibody or antigen-binding fragment inhibits a cellular response [~~is~~] selected from the group consisting of [~~Ca<sup>2+</sup> flux~~] proliferation, migration, chemotaxis, secretion, exocytosis, degranulation, inflammatory mediator release and respiratory burst.

26. (Amended) The antibody or antigen-binding fragment of Claim 24 wherein said antibody or antigen-binding fragment inhibits a cellular response, and said cellular response is chemotaxis.
35. (Three Times Amended) The isolated cell of Claim 34 wherein said antibody or antigen-binding fragment inhibits signal transduction and/or a cellular response [to] induced upon binding of ligand to said Bonzo in an *in vitro* assay with an IC<sub>50</sub> of less than about 7 µg/mL.
36. (Amended) The isolated cell of Claim 35 wherein said antibody or antigen-binding fragment inhibits a cellular response [is] selected from the group consisting of [Ca<sup>2+</sup>-flux] proliferation, migration, chemotaxis, secretion, exocytosis, degranulation, inflammatory mediator release and respiratory burst.
37. (Amended) The isolated cell of Claim 35 wherein said antibody or antigen-binding fragment inhibits a cellular response, and said cellular response is chemotaxis.
47. (Amended) A method of treating a subject having an inflammatory disease, comprising administering to said subject an effective amount of an [~~antagonist of mammalian Bonzo~~] antibody or antigen-binding fragment thereof which binds mammalian Bonzo and inhibits the binding of ligand thereto.
53. (Amended) A method of inhibiting a cellular response to binding of ligand to Bonzo expressed on the surface of a leukocyte in a mammal, comprising administering to said mammal an effective amount of an [~~antagonist of Bonzo~~] antibody or antigen-binding fragment thereof which binds mammalian Bonzo and inhibits the binding of ligand thereto.
60. (Amended) A method of modulating a Bonzo function comprising contacting a cell that expresses Bonzo with an [~~agent which binds~~] antibody or antigen-binding fragment thereof which binds mammalian Bonzo and inhibits the binding of ligand thereto, thereby modulating the function of said Bonzo.